版本:
中国

BRIEF-Asterias presents 9-month follow-up data from ongoing trial

June 13 Asterias Biotherapeutics Inc

* Asterias biotherapeutics inc - announced new 9-month follow-up data from ais-a 10 million cell cohort in company's ongoing scistar phase 1/2a clinical trial

* Asterias - new efficacy results show meaningful improvements in arm, hand, finger function in 10 million cell cohort treated with ast-opc1 cells been maintained

* Asterias biotherapeutics inc - new efficacy results show that some patients have been further enhanced even 9 months following dosing

* Asterias biotherapeutics inc - there have been no serious adverse events related to ast-opc1

* Asterias biotherapeutics inc - asterias will report 12-month efficacy and safety data from ais-a 10 million cell cohort sometime late in q3 2017

* Asterias biotherapeutics inc - trial results to date continue to indicate a positive safety profile for ast-opc1

* Asterias biotherapeutics inc - additional motor level improvement was seen in ais-a 10 million cell cohort at 9 months

* Asterias biotherapeutics-data shows 3/6 patients have now recovered 2 levels of motor function, previously-announced improvements in arm, hand, finger function

* Asterias biotherapeutics - data from study indicate ast-opc1 can be safely administered to patients in subacute period after severe cervical spinal cord injury

* Asterias biotherapeutics inc - trial results to date continue to indicate a positive safety profile for ast-opc1 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐